Yasheng Medicine -B(06855)： Two clinical studies will be presented at the annual meeting of the European Society of Oncology in 2023.
： Two clinical studies will be presented at the annual meeting of the European Society of Oncology in 2023.&w=360&h=215&c=1&rs=1.jpg)
Zhitong Finance APP News, Yasheng Medicine -B(06855) announced that the company will publish two clinical research results in the form of mini oral report and wall newspaper at the annual meeting of the European Society of Oncology (ESMO) in 2023: Bcl-2/Bcl-xL double target inhibitor APG-1252 combined with oxitinib in the treatment of non-small cell lung cancer with EGFR mutation. Clinical data of Nilic in TKI-resistant SDH- deficient gastrointestinal stromal tumor (GIST).
ESMO Annual Meeting is one of the most authoritative and influential oncology academic conferences in the world, displaying the latest cutting-edge data and research results. This ESMO annual meeting will be held in Madrid, Spain from October 20, 2023 to October 24, 2023.
The two latest clinical trials that Yasheng Medicine will present at this ESMO annual meeting include: the anti-tumor activity of Orobatinib (HQP1351) in patients with tyrosine kinase inhibitor (TKI)-resistant succinate dehydrogenase deficiency (SDH-) gastrointestinal stromal tumor (GIST); And the latest clinical research results of APG-1252 combined with oxitinib in the treatment of patients with EGFR mutation in non-small cell lung cancer (NSCLC).
Declaration: All article resources on this website, unless otherwise specified or labeled, are collected from online resources. If the content on this website infringes on the legitimate rights and interests of the original author, you can contact this website to delete it.
